SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five ...
MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...
The Global MRD Testing Market is expanding due to rising cancer and hematological malignancy rates and advances in diagnostic ...
NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...
Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...
About BioNexus Gene Lab Corp. BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a precision diagnostics company focused on Southeast Asia. BGLC operates laboratories and partnerships across the region and is ...
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
For patients with chronic lymphocytic leukemia (CLL), minimal residual disease (MRD) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment, and has ...
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoringMORRISVILLE, N.C.--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback